Low-level viremia in chronic hepatitis B patients treated with first-line treatment with nucleos(t)ide analogues and its treatment strategies
- VernacularTitle:一线核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的发生及治疗策略
- Author:
Rongjiong ZHENG
1
;
Xiaobo LU
Author Information
- Keywords: Hepatitis B,Chronic; Nucleosides; Nucleotides; Low-Level Viremia
- From: Journal of Clinical Hepatology 2024;40(5):880-883
- CountryChina
- Language:Chinese
- Abstract: Highly effective oral antiviral therapy with low drug resistance can strongly inhibit HBV replication;however,some patients may still have low-level viremia(LLV)after receiving entecavir,tenofovir disoproxil fumarate,tenofovir alafenamide,or tenofovir amibufenamide for 48 weeks or more.Multiple studies in China and globally show that LLV after antiviral therapy is closely associated with the progression of chronic hepatitis B liver fibrosis,the risk of decompensated liver cirrhosis and hepatocellular carcinoma,and the reduction in long-term survival rate.Therefore,this article reviews the development,risk factors,and clinical harm of LLV after first-line treatment with nucleos(t)ide analogues,as well as different treatment regimens,in order to provide a reference for the treatment of LLV in chronic hepatitis B patients in the future.
